Vistagen Therapeutics Profit Margin

Vistagen Therapeutics (VTGN) currently reports a profit margin of -2703.72% as of June 2026. That compares with -8634.67% in the prior-year period — up 68.7% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Vistagen Therapeutics's profit margin history and peer comparisons.

Vistagen Therapeutics's profit margin increased from -8634.67% to -2703.72% — a 68.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vistagen Therapeutics's profit margin of -2703.72% is lower than the Healthcare sector average of 21.34%. That is roughly 12772.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Vistagen Therapeutics's current -2703.72% should be judged against Healthcare norms (sector average: 21.34%) and against VTGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2703.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Vistagen Therapeutics, and consider following VTGN for alerts when major investors trade the stock.